• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

New test measures testosterone at low levels

Article

Abbott Laboratories has announced FDA clearance of a new testosterone test designed to accurately measure a wide range of testosterone levels seen in both men and women.

Abbott Laboratories has announced FDA clearance of a new testosterone test designed to accurately measure a wide range of testosterone levels seen in both men and women.

The ARCHITECT 2nd Generation Testosterone Assay “is more sensitive, accurate and precise than previous versions of the assay," said Frank Quinn, PhD, of Abbott. "The improved assay performance means physicians will be able to obtain more reliable measurements of testosterone and use this information to help guide patient treatment decisions."

The new assay runs on Abbott’s fully automated ARCHITECT family of analyzers. It is a chemiluminescent microparticle immunoassay for the quantitative determination of testosterone in human serum and plasma.

In male patients, measurements of testosterone are used in the diagnosis and treatment of disorders involving the male sex hormones, including primary and secondary hypogonadism, delayed or precocious puberty, and erectile dysfunction.

Related Videos
Michael S. Cookson, MD, MMHC, FACS, answers a question during a Zoom video interview
David Barquin, MD, answers a question during a Zoom video interview
Alexandra Tabakin, MD, answers a question during a Zoom video interview
Blurred interior of hospital |  Image Credit: © jakkapan - stock.adobe.com
Laura Bukavina, MD, MPH, answers a question during a Zoom video interview
Image of kidneys | Image Credit: © peterschreiber.media - stock.adobe.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.